FY2024 · ended Dec 31, 2024 · Revenue $119,371, -85.8% YoY · Filed Mar 31, 2026
Soligenix, Inc. (SNGX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$10.3 million. As of Jun 30, 2026 it held $9.8 million in cash and investments and $302,589 in total debt.
Revenue
$119,371
-85.8% vs prior year
Net income
$-11.08M
-34.0% vs prior year
Operating cash flow (TTM)
$-9.74M
-0.1% vs year-ago TTM
Free cash flow
$-10.27M
EPS
$-2.14
+57.0% vs prior year
Dividend per share
None
Shares outstanding
10.31M
+226.6% vs prior year
Net cash
$9.51M
as of Jun 30, 2026
Operating margin
-7907.7%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SNGX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Princeton, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 812796
- Former names
- SOLIGENIX, INC. (until Nov 2, 2026); DOR BIOPHARMA INC (until Sep 29, 2009); ENDOREX CORP (until Oct 24, 2001); IMMUNOTHERAPEUTICS INC (until Apr 30, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $119,371 | $839,359 | $948,911 | $824,268 |
| Operating income | -$11.8M | -$9.4M | -$7.7M | -$14.2M | -$13.1M |
| Net income | -$11.1M | -$8.3M | -$6.1M | -$13.8M | -$12.6M |
| Diluted EPS | -$2.14 | -$4.98 | -$12.66 | -$4.81 | -$4.69 |
| Operating cash flow | -$10.3M | -$8.4M | -$8.6M | -$12.6M | -$11.7M |
| Free cash flow | -$10.3M | — | — | — | — |
| Total assets | $9.2M | $9.0M | $9.8M | $14.3M | $26.9M |
| Total liabilities | $3.9M | $4.8M | $7.3M | $16.8M | $16.1M |
| Stockholders' equity | $5.3M | $4.1M | $2.5M | -$2.5M | $10.7M |
| Cash and investments | $7.9M | $7.8M | $8.4M | $13.4M | $26.0M |
| Total debt | $358,144 | $111,862 | $1.2M | $342,575 | $106,151 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results, Other events
|
Sep 21, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Other events
|
Jun 26, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Listing notice, Officer or director change, Other events
|
Jun 12, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Other events
|
May 28, 2026 | May 28, 2026 |
All 1001 Soligenix, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.